A61K 39/00117
Mucins
Official title: {Mucins, e.g. MUC-1}
A61K39/00117 (Mucins) appears on 175 US grants and 381 published applications in this corpus.
Search patents in A61K- Granted patents
- 175
- Published applications
- 381
- Assignees
- 177
- Inventors
- 601
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 11 |
| 2003 | 1 | 5 |
| 2004 | 0 | 7 |
| 2005 | 1 | 9 |
| 2006 | 0 | 9 |
| 2007 | 2 | 9 |
| 2008 | 1 | 7 |
| 2009 | 1 | 6 |
| 2010 | 1 | 10 |
| 2011 | 6 | 16 |
| 2012 | 5 | 15 |
| 2013 | 5 | 5 |
| 2014 | 7 | 20 |
| 2015 | 9 | 29 |
| 2016 | 11 | 34 |
| 2017 | 7 | 24 |
| 2018 | 12 | 24 |
| 2019 | 10 | 19 |
| 2020 | 12 | 27 |
| 2021 | 19 | 28 |
| 2022 | 12 | 23 |
| 2023 | 9 | 19 |
| 2024 | 10 | 12 |
| 2025 | 14 | 10 |
| 2026 | 6 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- Methods and vaccines for inducing immune responses to multiple different MHC molecules12 May 2026US 12,622,956 B2Mayo Foundation for Medical Education and Research
- T cell receptors and methods of use thereof12 May 2026US 12,624,082 B2University Health Network
- Anti-variable MUC1* antibodies and uses thereof24 Mar 2026US 12,583,927 B2Minerva Biotechnologies Corporation
- Methods of treating cancer3 Mar 2026US 12,565,682 B2NantCell, Inc.
- Cpg oligonucleotide and use thereof13 Aug 2026US 2026/0232792 A1Parr Biotechnology (Hebei) Co., Ltd.
- Methods of treating cancer4 Jun 2026US 2026/0152805 A1NantCell, Inc.
- Vaccine against pancreatic cancer, and medical use thereof12 Feb 2026US 2026/0041749 A1Yuanben (Zhuhai Hengqin) Biotechnology Co., Ltd.
- Fusion constructs and methods of using thereof23 Oct 2025US 2025/0325665 A1Precigen, Inc.
- Cancer vaccines targeting muc16 and uses thereof10 Jul 2025US 2025/0222086 A1Inovio Pharmaceuticals, Inc.
Most cited
By later US patents
- Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same90US 5,891,432 AThe Immune Response Corporation · 1999
- Antibodies to human carcinoma antigen83US 5,693,763 AEpigen, Inc. · 1997
- Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof79US 9,572,874 B2CureVac AG · 2017
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011